Sleep Initiation and Maintenance Disorders: Clinical Trials

136 trials for Sleep Initiation and Maintenance Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

82 completed, 13 terminated, 12 unknown, 11 recruiting. 136 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4136Completed 82, Terminated 13, Unknown 12, Recruiting 11, Not yet recruiting 8, Withdrawn 8, Active not recruiting 1, Enrolling by invitation 1

Follow Sleep Initiation and Maintenance Disorders: new trials by email Literature Review of Sleep Initiation and Maintenance Disorders trials Research Report on Sleep Initiation and Maintenance Disorders

Trials (filtered) newest first · largest first

All 136 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Suvorexant 3 - PE-PC
Suvorexant, Placebo, Prolonged Exposure Therapy for Primary Care (PE-PC) - PTSD - Post Traumatic Stress Disorder, Insomnia
Phase 4Not yet recruitingNorthern California Institute of Research and Education1422026-09-012026-07-07
Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease
Lemborexant, placebo - Parkinson's Disease, Insomnia
Phase 4Not yet recruitingYangPan442026-08-192026-06-11
Sleep Quality - Comparing the Effect of Ondansetron or Dexamethasone Given as Routine Prophylaxis Intraoperatively to Prevent Post Operative Nausea and Vomiting (SCORPION)
Dexamethasone (IV), Ondansetron iv - Postoperative Sleep Quality, Postoperative Behaviour
Phase 4Not yet recruitingTelethon Kids Institute5002026-08-172026-08-20
Evaluating the Efficacy and Safety of Daridorexant Transition From BZRAs in Insomnia Patients(EASY-TIP)
Daridorexant - Insomnia Disorders
Phase 4Not yet recruitingXuanwu Hospital, Beijing1562026-08-012026-07-29
The Effects of Orexin Antagonism on Fear Extinction in PTSD
Suvorexant, Placebo - Insomnia, PTSD
Phase 4RecruitingVA Office of Research and Development401202026-07-012026-11-05
A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia
Sleep Hygiene Education, Melatonin IR, 3 mg, Melatonin IR, 5 mg - Insomnia, Insomnia Disorder
Phase 4RecruitingUniversity of Pennsylvania12002026-05-012026-09-16
Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia
Daridorexant 50 mg, Placebo - Insomnia, Major Depressive Disorder
Phase 4Not yet recruitingInstitut d'Investigació Biomèdica de Bellvitge1342026-04-012026-04-29
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
Conversion to extended-release tacrolimus, Maintenance of immediate-release tacrolimus - Kidney Transplant Recipients, Old Age
Phase 4RecruitingMassachusetts General Hospital922026-03-172026-05-28
Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms
Cognitive behavioral therapy for insomnia (CBT-i), Trazodone, Daridorexant - Menopausal Women, Insomnia
Phase 4RecruitingBrigham and Women's Hospital10002026-02-132026-06-08
Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking
Daridorexant 50 mg, Placebo - Smoking, Nicotine
Phase 4Not yet recruitingLegacy Health System442026-02-102026-01-09
No More Sleepless Nights in Perimenopause
Cognitive Behavioural Therapy for Insomnia (CBT-I), Hormone Replacement Therapy (HRT), Sleep Hygiene - Insomnia, Menopause
Phase 4RecruitingInsel Gruppe AG, University Hospital Bern542026-01-012026-01-13
Compound Ciwujia Granules in the Treatment of Insomnia
Compound Ciwujia Granules group, Estazolam, Compound Ciwujia Granules and estazolam - Insomnia Disorder
Phase 4Not yet recruitingHui Zhu12002026-01-012025-12-29
Sleeping Through Menopause
Estrogens and Progestogens, Cognitive behavioral therapy for insomnia (CBTi), and circadian rhythm therapy - Menopause, Insomnia
Phase 4Not yet recruitingVU University of Amsterdam2222025-10-012025-08-24
EFFECT OF ZOLPIDEM ON SLEEP QUALITY AND OPIOID CONSUMPTION FOLLOWING PRIMARY TOTAL KNEE ARTHROPLASTY: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Zolpidem 10 mg tablets, Avocado-soybean unsaponifiables 300 mg - Postoperative Pain Management in Total Knee Arthroplasty
Phase 4CompletedSanatorio Allende542025-08-052026-09-03
The Role of mGluR5 in CBT-I
Cognitive Behavioral Therapy for Insomnia, PET Scan with [11C]ABP688 - Major Depressive Disorder (MDD)
Phase 4RecruitingStony Brook University422025-08-012026-11-10
Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.
Dolutegravir (DTG), Darunavir/Cobicistat (FDC) - HIV, Insomnia
Phase 4UnknownInstituto Mexicano del Seguro Social1402025-06-192025-06-26
Impact of Eszopiclone on Blood Pressure in Patients With Insomnia and Hypertension (PRYSMA-HTN)
Eszopiclone 3 mg, Placebo - Insomnia, Hypertension
Phase 4RecruitingUniversity of Sao Paulo1502025-06-042025-06-12
Efficacy of Melatonin Treatment on Sleep Quality Improvement in Inflammatory Bowel Disease Patients With Clinical Remission
Melatonin ("Circadin"), Placebo - IBD (Inflammatory Bowel Disease)
Phase 4RecruitingMahidol University902025-04-012026-08-04
Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients
Best Practice, Electronic Health Record Review, Interview - Advanced Malignant Solid Neoplasm, Delirium
Phase 4WithdrawnMayo Clinic2025-02-262025-05-01
Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients
5-hydroxytryptamine balanced antidepressants trazodone, Citalopram hydrobromide combined with zolpidem - Depressed Insomniac Co-morbid Patients
Phase 4RecruitingTongji University602025-01-012025-02-19

Showing 20 of 136. Sign in to see all of them.

Narrower conditions

Sleep Wake Disorders (15)  ·  Depression (10)  ·  Anxiety Disorders (8)  ·  Stress Disorders, Post-Traumatic (8)  ·  Depressive Disorder, Major (7)  ·  Fatigue (5)  ·  Parasomnias (5)  ·  Delirium (4)  ·  Agnosia (3)  ·  Attention Deficit Disorder with Hyperactivity (3)  ·  Hot Flashes (3)  ·  Hypertension (3)  ·  Pain (3)  ·  Sleep Deprivation (3)

Broader conditions

Dyssomnias (136)  ·  Nervous System Diseases (136)  ·  Sleep Disorders, Intrinsic (135)  ·  Mental Disorders (134)  ·  Sleep Wake Disorders (121)  ·  Pathological Conditions, Signs and Symptoms (44)  ·  Signs and Symptoms (42)  ·  Neurologic Manifestations (33)  ·  Behavior (14)  ·  Central Nervous System Diseases (12)  ·  Brain Diseases (11)  ·  Behavioral Symptoms (10)  ·  Mood Disorders (9)  ·  Pathologic Processes (9)  ·  Neurobehavioral Manifestations (8)

Interventions

Zolpidem (22)  ·  suvorexant (22)  ·  Eszopiclone (18)  ·  ramelteon (14)  ·  Cognitive Behavioral Therapy (9)  ·  Dexmedetomidine (6)  ·  daridorexant (6)  ·  Sugars (5)  ·  Saline Solution (4)  ·  Trazodone (4)  ·  Escitalopram (3)  ·  Melatonin (3)  ·  lemborexant (3)  ·  Atomoxetine Hydrochloride (2)  ·  Doxepin (2)

Sponsors

Peking University First Hospital (6)  ·  Sanofi (5)  ·  Takeda (5)  ·  Astellas Pharma Inc (4)  ·  Brigham and Women's Hospital (4)  ·  Duke University (4)  ·  Massachusetts General Hospital (4)  ·  Henry Ford Health System (3)  ·  University of Pennsylvania (3)  ·  VA Office of Research and Development (3)  ·  Baylor College of Medicine (2)  ·  China Medical University, China (2)  ·  Laval University (2)  ·  Rhode Island Hospital (2)  ·  Sumitomo Pharma America, Inc. (2)

Countries

United States (77)  ·  China (13)  ·  Brazil (6)  ·  Canada (6)  ·  Japan (6)  ·  France (3)  ·  Switzerland (3)  ·  Norway (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Argentina (1)  ·  Australia (1)  ·  Belgium (1)  ·  Germany (1)  ·  Hungary (1)

Top investigators

Dong-Xin Wang, MD, PhD (4)  ·  Phyllis Diener (3)  ·  Andrew D Krystal, MD (2)  ·  Andrew Krystal, MD (2)  ·  Daniel J. Buysse, MD (2)  ·  Dong-Xin Wang, MD,PhD (2)  ·  Melissa B Jones, MD (2)  ·  Michael L Perlis, PhD (2)  ·  Sabra S Inslicht, PhD (2)  ·  Albert J Arias, MD, MS (1)  ·  Ali El Solh, MD (1)  ·  An Mariman, MD (1)  ·  Andrea H. Weinberger, Ph.D. (1)

Results publications

PMID 15683149, PMID 16804151, PMID 17068990, PMID 18417099, PMID 18458207, PMID 18584227, PMID 18627623, PMID 19151617, PMID 19317379, PMID 19454639, PMID 19724732, PMID 20175406, PMID 20478741, PMID 20581790, PMID 20726279, PMID 20814317, PMID 21116652, PMID 21208574, PMID 21208597, PMID 21447050, PMID 21601519, PMID 21623982, PMID 21734685, PMID 22131611, PMID 22232986, PMID 22334811, PMID 23143411, PMID 23514019, PMID 23563887, PMID 24090266, PMID 24399070, PMID 24733354, PMID 24882900, PMID 25323219, PMID 26763501, PMID 26963600, PMID 27648659, PMID 27658218, PMID 28143413, PMID 28241153, PMID 28364426, PMID 28473524, PMID 28652381, PMID 29265834, PMID 30871960, PMID 31238203, PMID 31537089, PMID 31538599, PMID 31859791, PMID 31992394

NIH funding

2015 (2), 2023 (1), 2025 (1), I01CX001814 (1), I01CX001957 (1), I01CX002734 (1), K23MH066978 (1), R01AG054521 (1), R01HL162799 (1), R01MH024652 (1), R01MH060413 (1), R01MH095776 (1), R01MH137211 (1), R34MH070821 (1), R34MH091338 (1)